Dr Shobhit Baijal is a leading Consultant Medical Oncologist at the HCA Harborne Hospital in Birmingham and an Honorary Associate Professor at The University of Birmingham. He is a renowned expert in the Oncological management of all forms of Lung, Colorectal and Liver malignancies.

Dr Baijal completed his medical training at St Bartholomew's Medical School, including a First Class BSc Honours in immunology and cell pathology from University College London. He went on to specialise in Medical Oncology in the West Midlands and was appointed Consultant to University Hospitals Birmingham NHS Trust in 2011.

Dr Baijal actively treat lung, colorectal and liver cancer across multiple hospital sites within the West Midlands. He specialises in all forms of cancer drug treatments including chemotherapy, immuno-oncology, precision oncology and chemoembolisation.

He has a large Clinical Trial portfolio and is the UK Chief and Principle Investigator for National and International studies. He works closely with Pharmaceutical companies to access novel drugs for his patients. Dr Baijal has published extensively and regularly presents at regional, national and international cancer meetings. He is an invited Medical Expert for NICE committee reviews for new anti-cancer drug therapies.

As a Steering Committee member of the British Thoracic Oncology Group he has a pivotal role in supporting and educating Thoracic Oncology professionals across the United Kingdom. He is an Honorary Clinical Advisor for EGFR positive UK, on the Expert Panel for Roy Castle Foundation and is also an advisor to ALK Positive UK.

Dr Baijal aims to deliver cutting edge, individualised and evidence-based cancer treatments for his patients whilst ensuring their health and wellbeing is also prioritised.